On a preliminary basis, Neurocrine Biosciences (NASDAQ:NBIX) expects Ingrezza (valbenazine) sales in Q4 and 2019 to be ~$238M (+83%) and ~$753M (+84%), respectively.
Quick assets at year-end: $970M.
Q1 2020 Ingrezza sales to be negatively impacted by payer-related seasonal dynamics, gross-to-net discount increases from payers, Medicare Part D rebates and potential reduction in channel inventory.
Management does not intend to guide on 2020 Ingrezza sales.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.